A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.
作者信息
El Jurdi Najla, Holtzman Noa G, Hishmeh Rania, Mina Alain, Schulz Eduard, Stokes Anita, Li Grace, Schmidt Keith T, Figg William D, Micheletti Nicholas, Mays Jacqueline W, Cowen Edward W, Pavletic Steven Z, Pusic Iskra
机构信息
Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
出版信息
Br J Haematol. 2025 Jun;206(6):1822-1827. doi: 10.1111/bjh.20069. Epub 2025 May 5.
Abstract
摘要
相似文献
1
A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.单药伊布替尼一线治疗慢性移植物抗宿主病的2期研究：一种新范式及经验教训。
Br J Haematol. 2025 Jun;206(6):1822-1827. doi: 10.1111/bjh.20069. Epub 2025 May 5.
2
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.慢性移植物抗宿主病治疗随时间的变化：德国、奥地利和瑞士异基因造血干细胞移植中心的15年调查
Transplant Cell Ther. 2025 Jul;31(7):450.e1-450.e10. doi: 10.1016/j.jtct.2025.04.017. Epub 2025 May 5.
3
Effectiveness of ibrutinib in the management of chronic GVHD.伊布替尼在慢性移植物抗宿主病管理中的有效性。
Transfus Apher Sci. 2025 Feb;64(1):104052. doi: 10.1016/j.transci.2024.104052. Epub 2024 Dec 16.
4
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.多克隆抗胸腺细胞球蛋白用于预防成人异基因干细胞或骨髓移植后的移植物抗宿主病。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD009159. doi: 10.1002/14651858.CD009159.pub2.
5
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.用于预防成人异基因干细胞或骨髓移植后移植物抗宿主病的多克隆抗胸腺细胞球蛋白。
Cochrane Database Syst Rev. 2023 Jun 21;6(6):CD009159. doi: 10.1002/14651858.CD009159.pub3.
6
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植。
Cochrane Database Syst Rev. 2024 Nov 7;11(11):CD010189. doi: 10.1002/14651858.CD010189.pub3.
7
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.与一线使用环孢素和/或抗胸腺细胞或抗淋巴细胞球蛋白治疗获得性重型再生障碍性贫血相比，HLA匹配的同胞供者进行一线异基因造血干细胞移植的情况。
Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD006407. doi: 10.1002/14651858.CD006407.pub2.
8
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.儿童造血干细胞移植后慢性移植物抗宿主病的体外光化学疗法与替代治疗对比
Cochrane Database Syst Rev. 2015 Dec 15;2015(12):CD009898. doi: 10.1002/14651858.CD009898.pub3.
9
Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs.面对有效药物的快速发展，瑞士异体造血细胞移植治疗慢性髓性白血病。
Swiss Med Wkly. 2024 May 3;154:3754. doi: 10.57187/s.3754.
10
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.体外光分离术与其他治疗方案在儿童和青少年造血干细胞移植后慢性移植物抗宿主病中的比较。
Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD009898. doi: 10.1002/14651858.CD009898.pub4.
本文引用的文献
1
Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.慢性移植物抗宿主病，第2部分：临床成功与未来路线图。
Transplantation. 2025 Feb 7. doi: 10.1097/TP.0000000000005345.
2
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.伊布替尼治疗类固醇难治性慢性移植物抗宿主病：一项多中心真实世界分析。
Blood Adv. 2025 Mar 11;9(5):1040-1048. doi: 10.1182/bloodadvances.2024014374.
3
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.阿西米单抗治疗复发性或难治性慢性移植物抗宿主病。
N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537.
4
Chronic graft-versus-host disease: unresolved complication or ancient history?慢性移植物抗宿主病：未解决的并发症还是古老的历史？
Blood. 2024 Sep 26;144(13):1363-1373. doi: 10.1182/blood.2023022735.
5
Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.泼尼松和依维莫司治疗新诊断的中度或重度慢性移植物抗宿主病（PredEver 研究）：一项前瞻性多中心 IIA 期研究。
Bone Marrow Transplant. 2024 Aug;59(8):1092-1096. doi: 10.1038/s41409-024-02289-0. Epub 2024 May 2.
6
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.伊布替尼作为慢性移植物抗宿主病一线治疗的疗效：来自随机 III 期 iNTEGRATE 研究的结果。
J Clin Oncol. 2023 Apr 1;41(10):1876-1887. doi: 10.1200/JCO.22.00509. Epub 2023 Jan 6.
7
Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT.中重度慢性移植物抗宿主病的无类固醇一线治疗：欧洲血液与骨髓移植协会移植并发症工作小组的一项调查
Bone Marrow Transplant. 2023 Mar;58(3):325-327. doi: 10.1038/s41409-022-01881-6. Epub 2022 Nov 29.
8
Three US Food and Drug Administration-approved therapies for chronic GVHD.三种美国食品和药物管理局批准的慢性移植物抗宿主病治疗方法。
Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.
9
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.慢性移植物抗宿主病的初始治疗：实践差异和无失败生存分析。
Blood Adv. 2021 Nov 23;5(22):4549-4559. doi: 10.1182/bloodadvances.2021005286.
10
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.慢性移植物抗宿主病患者的非复发死亡率：慢性移植物抗宿主病联盟的更新分析。
Blood Adv. 2021 Oct 26;5(20):4278-4284. doi: 10.1182/bloodadvances.2021004941.
Zotero 插件